Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Baseline features of the Severe Asthma Research Program (SARP III) cohort: Differences with age. J Allergy Clin Immunol Pract 2018;6:545-554.e4.
Hastie AT, Mauger DT, Denlinger LC, Coverstone A, Castro M, Erzurum S, et al. Mixed sputum granulocyte longitudinal impact on lung function in the Severe Asthma Research Program. Am J Respir Crit Care Med 2021;203:882-892.
Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: Assessment and identification using induced sputum. Respirology 2006;11:54-61.
Newby C, Agbetile J, Hargadon B, Monteiro W, Green R, Pavord I, et al. Lung function decline and variable airway inflammatory pattern: Longitudinal analysis of severe asthma. J Allergy Clin Immunol 2014; 134:287-294.
Frix AN, Schleich F, Paulus V, Guissard F, Henket M, Louis R. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. Biochem Pharmacol 2020;179:113944.
Schleich F, Graff S, Nekoee H, Moermans C, Henket M, Sanchez C, et al. Real-word experience with mepolizumab: Does it deliver what it has promised? Clin Exp Allergy 2020;50:687-695.
Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013;13:11.
Demarche SF, Schleich FN, Paulus VA, Henket MA, Van Hees TJ, Louis RE. Asthma control and sputum eosinophils: A longitudinal study in daily practice. J Allergy Clin Immunol Pract 2017;5: 1335-1343.e5.
Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002;360: 1715-1721.
Peters MC, McGrath KW, Hawkins GA, Hastie AT, Levy BD, Israel E, et al.; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: A cross-sectional analysis of two cohorts. Lancet Respir Med 2016;4:574-584.
Peters MC, Mauger D, Ross KR, Phillips B, Gaston B, Cardet JC, et al. Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency. Am J Respir Crit Care Med 2020;202: 973-982.
Liu H, Lazarus SC, Caughey GH, Fahy JV. Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro. Am J Physiol 1999;276:L28-L34.
Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA 2012; 109:1673-1678.
Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: Identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-879.
Demarche S, Schleich F, Henket M, Paulus V, Louis R, Van Hees T. Step-down of inhaled corticosteroids in non-eosinophilic asthma: A prospective trial in real life. Clin Exp Allergy 2018;48:525-535.
Heaney LG, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker SM, et al.; investigators for the MRC Refractory Asthma Stratification Programme. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: A multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med 2021;9: 57-68.
Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID. Optimal asthma control: Time for a new target. Am J Respir Crit Care Med 2020;201:1480-1487.
